Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables (2016 - 2025)

Historic Receivables for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to $26.8 million.

  • Gyre Therapeutics' Receivables rose 2846.72% to $26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.8 million, marking a year-over-year increase of 2846.72%. This contributed to the annual value of $24.2 million for FY2024, which is 5536.27% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Receivables stood at $26.8 million, which was up 2846.72% from $25.4 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Receivables peaked at $26.8 million during Q3 2025, and registered a low of $564000.0 during Q1 2022.
  • Moreover, its 5-year median value for Receivables was $15.6 million (2023), whereas its average is $12.4 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Receivables tumbled by 4512.53% in 2021, and later skyrocketed by 84257.43% in 2022.
  • Gyre Therapeutics' Receivables (Quarter) stood at $1.8 million in 2021, then skyrocketed by 842.57% to $17.1 million in 2022, then fell by 9.24% to $15.6 million in 2023, then soared by 55.36% to $24.2 million in 2024, then grew by 10.79% to $26.8 million in 2025.
  • Its last three reported values are $26.8 million in Q3 2025, $25.4 million for Q2 2025, and $22.5 million during Q1 2025.